niacinamide has been researched along with decitabine in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Biacsi, R; Kumari, D; Usdin, K | 1 |
Büchner, T; Krug, U; Lübbert, M | 1 |
Ford, LA; Freyer, CW; Griffiths, EA; Muppidi, MR; Portwood, S; Thompson, JE; Wang, ES; Wetzler, M | 1 |
Gu, J; Huang, W; Mao, X; Wang, Y; Wang, Z; Xiao, M; Zhu, L | 1 |
1 review(s) available for niacinamide and decitabine
Article | Year |
---|---|
Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?
Topics: Azacitidine; Benzenesulfonates; Decitabine; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Prenylation; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Staurosporine | 2010 |
4 other study(ies) available for niacinamide and decitabine
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome.
Topics: Alleles; Azacitidine; Base Sequence; Cell Line; Decitabine; DNA Methylation; DNA Primers; Enzyme Inhibitors; Female; Fragile X Mental Retardation Protein; Fragile X Syndrome; Gene Silencing; Histones; Humans; Hydroxamic Acids; Models, Biological; Mutation; Naphthalenes; Niacinamide; Promoter Regions, Genetic; Pyrones; Sirtuin 1; Sirtuins; Trinucleotide Repeat Expansion | 2008 |
Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis | 2015 |
Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib.
Topics: Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |